AOBiome - Transforming human health through the restoration of Ammonia-Oxidizing Bacteria

AOBiome Launches Phase 2 Clinical Trial Using Novel Bacterial Platform for Treatment of Hypertension

AOBiome Launches Phase 2 Clinical Trial Using Novel Bacterial Platform for Treatment of Hypertension.

More Than 150M People Affected by Hypertension in the US Could Benefit From Patented AOB Treatment

Read More

Aobiome

AOBiome is a Boston and San Francisco based biotech company focused on transforming human health through products that restore ammonia-oxidizing bacteria (AOBs) which current hygiene practices have stripped from the modern microbiome. Founded in 2013 by MIT Chemical Engineer David Whitlock and Patients Like Me founder Jamie Heywood along with co-founders Hilly Thompson and Lenny Barshack. The company is developing a novel class of therapeutics to improve skin health, hypertension, and other systemic conditions. AOBs convert ammonia to nitrite, an anti-microbial compound, and nitric oxide, a well-documented signaling molecule in the inflammatory process. AOBiome also owns the Mother Dirt branded line of consumer biome-friendly products targeted at restoring and maintaining the delicate balance of the skin biome.

Read More

Therapeutic Product Pipeline

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Mild to Moderate Acne
  • Hypertension
  • Allergic Rhinitis
  • Pruritis/Eczema
  • Wound Healing
  • Thermo Regulation

THE STORY OF AOBIOME

"Why do horses roll around in the dirt?"

This question asked in the context of the microbiome has led to the discovery of the evolutionary role of AOBs. Founder David Whitlock's curiosity and nontraditional methods not only discovered the link between AOBs and human health, but also the methods to re-introduce them into the modern microbiome - even if that meant giving up showering for a while…

Read More

NITRIC OXIDE

Nitric oxide is an important signaling molecular involved in many physiological and pathological processes. Nitric oxide was named "Molecular of the Year" by the American Association for the Advancement of Science and has been shown to have a significant role in vasodilation amongst other pathways. The Nitrosomonas bacteria being studied by AOBiome consume ammonia and produce nitric oxide, providing an effective delivery mechanism for this crucial molecule.

Read More

RISE OF HYGIENE, RISE OF INFLAMMATION

Conditions like acne, eczema, rosacea, and peanut allergies are not evolutionary in nature, but rather recent additions to the health lexicon. Children now sit at peanut free tables at school, a phenomenon unfamiliar to lunchrooms of previous generations. Even more troubling is the recent rise of Alpha-gal, an allergic reaction to meat.

READ MORE

BIOME FRIENDLY

In support of our mission, we have developed beauty and hygiene products that support the skin microbiome. As part of this process, we have developed strict criteria for ingredient selection, formulation, packaging, and manufacturing in addition to our trademarked "Biome Friendly" assay.

Shop Now

White House launches the National Microbiome Initiative.

Learn More

Recent News

April 17, 2017
AOBiome Completes Patient Enrollment In Phase 2 Clinical Trial Of Lead Candidate B244 To Treat Elevated Blood Pressure
Read More
January 5, 2017
AOBiome Partners with iCarbonX and Secures $30 Million Investment for Drug Development
Read More
December 16, 2016
AOBiome Launches Phase 2 Clinical Trial Using Novel Bacterial Platform for Treatment of Hypertension
Read More
View All

Newsletter